

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

**CHANGES OF INDEPENDENT NON-EXECUTIVE DIRECTORS
AND COMPOSITION OF BOARD COMMITTEES
AND
CHANGES OF CLOSURE PERIOD OF REGISTER OF MEMBERS AND
DATE OF PAYMENT FOR PROPOSED FINAL DIVIDEND**

RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (“**Director(s)**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. CHENG Xinxin (“**Ms. Cheng**”) has resigned from the position of an independent non-executive Director, the chairlady of the audit committee (the “**Audit Committee**”) and a member of the nomination committee (the “**Nomination Committee**”) of the Company with effect upon the conclusion of the forthcoming annual general meeting of the Company (the “**AGM**”), which is expected to be held on 31 May 2019, in order to devote more time to her family.

Ms. Cheng has confirmed that she has no claim whatsoever against the Company for fees, compensation for loss of office, remuneration, severance payments, pension, expenses or otherwise and has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Ms. Cheng towards the Company during her tenure of office.

APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board resolved that an ordinary resolution will be proposed at the AGM to appoint Ms. CHEN Yujun (“**Ms. Chen**”) as an independent non-executive Director with effect from the conclusion of the AGM to succeed Ms. Cheng. The Board and the Nomination Committee of the Company considered that Ms. Chen has satisfied the independence guidelines set out in Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). Subject to the approval by the Shareholders of the appointment of Ms. Chen as an independent non-executive Director, the Board also resolved to appoint Ms. Chen as the chairlady of the Audit Committee and as a member of the Nomination Committee at the conclusion of the AGM.

Ms. CHEN Yujun

Ms. CHEN Yujun (陳玉君), aged 39, has over 13 years of experience in auditing, accounting and corporate finance. She has been a member of The Chinese Institute of Certified Public Accountants since 2010 and obtained a bachelor's degree in arts and a bachelor's degree in management from Guangdong University of Foreign Studies* (廣東外語外貿大學) in 2005. Ms. Chen has been the vice general manager of financial management center of Guangzhou Fineland Real Estate Development Co., Ltd.* (廣州市方圓房地產發展有限公司) since February 2018. Prior to that, she worked with Shanghai Eyugame Network Technology Co., Ltd.* (上海易娛網絡科技有限公司) as the chief financial officer from March 2016 to February 2018; worked with the Group as the chief financial officer from April 2014 to March 2016 and as deputy chief financial officer from May 2013 to March 2014; worked with KPMG in the audit department from July 2005 to May 2012 at various posts.

Subject to the Shareholders' approval at the AGM, Ms. Chen will enter into a letter of appointment with the Company to act as an independent non-executive Director for an initial term of three years commencing on the date of the AGM, subject to the rotation and re-election provisions in accordance with the articles of association of the Company and the Corporate Governance Code of the Listing Rules, and can be terminated by the Company or Ms. Chen by giving not less than three months' notice in writing or in other ways in accordance with the terms of the service agreement. Pursuant to the terms of the service agreement, Ms. Chen will receive a director's fee of HKD150,000 per year, which is determined with reference to the market rate and her time, effort and expertise to be devoted to the Company's affairs and the Company's remuneration policy.

Save as disclosed in this announcement, Ms. Chen (i) did not hold any other positions in the Company or its subsidiaries; (ii) had no other relationship with any Directors, senior management or substantial or controlling Shareholders of the Company; and (iii) did not hold any other directorships in listed public companies in the three years prior to the date of this announcement.

As of the date of this announcement, Ms. Chen does not have, and/or is not deemed to have any interest or short position in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Future Ordinance, Chapter 571 of the Laws of Hong Kong).

To the best of the knowledge, information and belief of our Directors having made all reasonable enquiries, there is no other information relating to the appointment of Ms. Chen that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend its welcome to Ms. Chen on her appointment.

CHANGES OF CLOSURE OF PERIOD OF REGISTER OF MEMBERS AND DATE OF PAYMENT FOR PROPOSED FINAL DIVIDEND

Reference is made to the annual results announcement dated 20 March 2019 of the Company for the year ended 31 December 2018 (the “**Results Announcement**”) in relation to, among other matters, the period of closure of registered members and the date of payment of the proposed final dividend of the Company. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meaning as those defined in the Results Announcement.

As disclosed in the Results Announcement, the Board proposed to declare a final dividend of HKD0.20 per ordinary share of the Company (“**Final Dividend**”). Subject to approval by the Shareholders at the AGM, the proposed Final Dividend was initially expected to be paid on or about Monday, 17 June 2019 to Shareholders whose name appear on the registered of members of the Company on Monday, 10 June 2019.

As additional time is required to complete the relevant administrative procedure for the payment of Final Dividend, the period of closure of the register of members of the Company for the purpose of determining the entitlements to and the expected payment date of the proposed Final Dividend will be changed as below:

Latest time to lodge transfer 4:30 p.m. on 10 June 2019 (Monday)

Closure dates of register of members
(both days inclusive) 11 June 2019 (Tuesday) to 14 June 2019 (Friday)

Record date 14 June 2019 (Friday)

Proposed Final Dividend expected payment date 21 June 2019 (Friday)

During the period of closure of register of members, no share transfers will be registered. For registration, all completed transfer documents accompanied by the relevant share certificates must be lodged with the Company branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.

By order of the Board of
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 23 April 2019

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive directors.

* *for identification only*